CHRNA1 and myasthenia gravis: The RINOMAX trial, a randomized controlled study, evaluated the effectiveness and safety of RTX in 87 participants with new-onset MG, encompassing AChRA-positive, MUSK-positive, and seronegative MG, with an average age of 67.4 (±13.4) years.